InsidersTradesSigma
Follow the Akeso, Inc. stock price and the full management transaction log of the company, a publicly traded company based in Hong Kong. Shares are listed on HK HK, under the supervision of HKEX. Market capitalisation: €87.3bn. The latest transaction was disclosed on 31 July 2026 (Purchase). Among the most active insiders: Xia Yu. The full history is free.
Analysts rate Akeso, Inc. Strong Buy (bullish), based on 20 analysts. Average price target: HK$169.73.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
10 of 10 declarations
Akeso, Inc. is a biopharmaceutical company focused on developing innovative treatments for autoimmune diseases and cancers. It specializes in the research and commercialization of monoclonal antibody-based drugs.